Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment

Lung Cancer

Volumn 60, Issue 2, 2008, Pages 215-221

  Lin, Zhong Zhe ^a   Hsu, Chiun ^a   Chang, Yeun Chung ^a   Yu, Chong Jen ^a   Hsu, Chih Hung ^a   Lin, Chia Chi ^a   Cheng, Ann Lii ^a   Yang, Pan Chyr ^a   Yang, Chih Hsin ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Gefitinib; Gemcitabine; Nonsmall cell lung cancer; Paclitaxel; Platinum; Second line chemotherapy; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PACLITAXEL;

EID: 42949152329     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.10.002     Document Type: Article

References (32)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
2. Le Chevalier T., Brisgand D., Douillard J.Y., Pujol J.L., Alberola V., Monnier A., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12 (1994) 360-367
3. Bonomi P., Kim K., Fairclough D., Cella D., Kugler J., Rowinsky E., et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18 (2000) 623-631
4. Langer C.J., Leighton J.C., Comis R.L., O'Dwyer P.J., McAleer C.A., Bonjo C.A., et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis. J Clin Oncol 13 (1995) 1860-1870
5. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al., The TAX 326 Study Group. Randomized, multinational phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 21 (2003) 3016-3024
6. Crino L., Scagliotti G.V., Ricci S., De Marinis F., Rinaldi M., Gridelli C., et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian lung cancer project. J Clin Oncol 17 (1999) 3522-3530
7. Gridelli C., Gallo C., Shepherd F.A., Illiano A., Piantedosi F., Robbiati S.F., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 (2003) 3025-3034
8. Anderson H., Lund B., Bach F., Thatcher N., Walling J., and Hansen H.H. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 12 (1994) 1821-1826
9. Murphy W.K., Fossela F.V., Winn R.J., Shin D.M., Hynes H.E., Gross H.M., et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85 (1993) 384-388
10. Le Chevalier T. The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer. Semin Oncol 4 Suppl 10 (2003) 37-44
11. Eisenhauer E.A., ten Bokkel Huinink W.W., Swenerton K.D., Gianni L., Myles J., van der Burg M.E., et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12 (1994) 2654-2666
12. Fidias P., Supko J.G., Martins R., Boral A., Carey R., Grossbard M., et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 7 (2001) 3942-3949
13. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
14. UICC. TNM classification of malignant tumours. 5th ed (1997), Wiley-Liss, New York
15. AJCC. AJCC Cancer Staging Manual. 5th ed (1997), Lippincott-Raven, Philadelphia
16. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
17. Wakelee H., and Belani C.P. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 10 Suppl 3 (2005) 1-10
18. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
19. Barlesi F., and Pujol J.L. Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials. Lung Cancer 49 (2005) 289-298
20. Pujol J.L., Barlesi F., and Daures J.P. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? a meta-analysis of phase III randomized trials. Lung Cancer 51 (2006) 335-345
21. De Pas T., Putzu C., Curigliano G., Noberasco C., Sabrina B., Catania C., et al. A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. Lung Cancer 54 (2006) 359-364
22. Kosmidis P., Mylonakis N., Nicolaides C., Kalophonos C., Samantas E., Boukovinas J., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20 (2002) 3578-3585
23. Smit E.F., van Meerbeeck J.P., Lianes P., Debruyne C., Legrand C., Schramel F., et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21 (2003) 3909-3917
24. Norton L., and Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61 (1977) 1307-1317
25. Day R.S. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 46 (1986) 3876-3885
26. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al., The TAX 320 Non-Small Cell Lung Cancer Study Group. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18 12 (2000) 2354-2362
27. Edelman M.J., and Gandara D.R. Sequential chemotherapy: rationale and clinical trial design in advanced non-small-cell carcinoma. Clin Lung Cancer 1 (1999) 122-127
28. De Pas T., de Braud F., Mandala M., Curigliano G., Catania C., Ferretti G., et al. Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. Lung Cancer 31 2-3 (2001) 267-270
29. Makrantonakis P., Ziotopoulos P., Agelidou A., Polyzos A., Ziras A., Chandrinos V., et al., Lung Cancer Committee of the Hellenic Oncology Research Group. Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study. Lung Cancer 53 1 (2006) 85-90
30. Agelaki S., Bania H., Kouroussis C., Blazoyiannakis G., Souglakos J., Tsiafaki X., et al. Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer A multicenter phase II study. Lung Cancer 34 Suppl 4 (2001) S77-S80
31. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 9496 (2005) 1527-1537
32. Chang A., Parikh P., Thongprasert S., Tan E.H., Perng R.P., Ganzon D., et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 1 (2006) 847-855